Detection Objectives and Core Concepts
purpose
In cell and gene therapy (CGT), Replication-Competent Virus (RCV) testing serves as a critical quality control and safety measure. This test detects replication-competent viruses that may arise during manufacturing through recombination or mutation, thereby preventing risks such as immune responses or tumorigenesis in patients.
Definition
Viral vectors commonly used in CGT-including AAV, lentivirus, retrovirus, and adenovirus-are typically replication-defective by design. However, during production, they may acquire replication competence through homologous or non-homologous recombination, or reversion mutations. This results in replication-competent variants such as rcAAV, RCL, RCR, and RCA, which can replicate autonomously and remain infectious under permissive conditions.
Main Targets for Testing
Typical RCV Risk Scenarios by Vector Type :
|
Vector Type |
RCV Type |
Typical Risk Scenarios |
|
Adeno-associated virus (AAV) |
Replication-competent AAV (rcAAV) |
In the presence of helper virus, rcAAV can replicate, potentially triggering immune responses and increasing tumorigenic risk. |
|
Lentiviral vector (LV) |
Replication-competent Lentivirus (RCL) |
HIV-1-derived vectors may undergo reversion mutations, restoring pathogenic potential. |
|
Retroviral vector (RV) |
Replication-competent retrovirus (RCR) |
Reversion mutations may lead to abnormal cell proliferation and insertional mutagenesis. |
|
Adenovirus (AdV) |
Replication-competent adenovirus (RCA) |
ΔE1-deleted vectors may recombine with E1 sequences in producer cells (e.g., HEK293), regenerating wild-type replication-competent virus. |
Advantages of Our RCV detection Platform
HyQure Biotech has established comprehensive detection capabilities for replication-competent viruses (RCVs), including rcAAV, RCL, RCR, and RCA. Our rcAAV assay is CNAS-certified. Our multi-dimensional RCV detection system delivers three core advantages-accuracy, speed, and regulatory compliance. The cell culture method serves as the gold standard; combined with endpoint detection, it specifically identifies infectious RCVs, directly addressing clinical safety risks while meeting all regulatory testing requirements.